Respiratory Syncytial Virus Infection
📧 Sign up to get email alerts when something new happens for Respiratory Syncytial Virus Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Preparedness Through Respiratory Virus Epidemiology and Community Engagement
A University of California, San Diego-led clinical trial studies respiratory virus epidemiology and community engagement to improve prepared…
-
CLINICAL_TRIALS trial_result · 2025-10-29Clinical Trial Update: Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) [Phase 3]
Phase 3 trial MK-1654-007 evaluating Clesrovimab in infants and children at increased risk for severe respiratory syncytial virus infection …
-
CLINICAL_TRIALS trial_result · 2025-10-27Clinical Trial Update: Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) [Phase 4]
Phase 4 clinical trial assessing the immunogenicity of respiratory syncytial virus vaccines in residents of long-term care facilities; resul…
-
FDA approval · 2025-10-20FDA Approved: BEYFORTUS — Supplemental Application (Sanofi Vaccines US Inc.)
FDA approved a supplemental application for Beyfortus (nirsevimab) from Sanofi Vaccines US Inc., related to an update/expansion of the produ…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings [NA]
The document reports on the clinical validation of Aptitude Medical Systems' Metrix Respiratory Panel for detecting COVID-19, Influenza A, I…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-10-07Clinical Trial Update: A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model [Phase 2]
This update reports results from a controlled Phase 2a trial evaluating EDP-323 for respiratory syncytial virus infection in a virus challen…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: RSV Immunogenicity Study in the Elderly (RISE) [Phase 3]
A Phase 3 immunogenicity study evaluating an RSV vaccine in elderly participants is currently recruiting. The trial aims to assess immune re…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy
A clinical trial update on Pfizer's ABRYSVO maternal RSV vaccine during pregnancy, focusing on its impact and effectiveness.
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults [Phase 1]
Phase 1 study of VXB-241, an RSV-HMPV bivalent vaccine, conducted by Vicebio Australia Proprietary Limited. The trial's listed population is…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: A Study to Evaluate Community-Based Measures to Increase RSV Vaccine Use Among Latino Adults [NA]
This study tests community-based strategies to increase uptake of the RSV vaccine among Latino adults and is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above [Phase 3]
A Phase 3 study evaluating the immune response and safety of GlaxoSmithKline's RSV vaccine in adults aged 18 to 49 at increased risk for RSV…
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults. [Phase 3]
Pfizer reported results from a Phase 3 study evaluating the safety, tolerability and immunogenicity of RSVpreF delivered in multidose vials …
-
CLINICAL_TRIALS trial_result · 2025-09-19Clinical Trial Update: First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory
The study reports on the first-year impact of Nirsevimab on pediatric Respiratory Syncytial Virus infection and related hospitalisations in …
-
CLINICAL_TRIALS other · 2025-09-16Clinical Trial Update: Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age [Phase 1]
A Phase 1 trial update evaluating safety and immunogenicity of investigational vaccines using the RSV monovalent antigen in healthy adults 1…
-
CLINICAL_TRIALS trial_result · 2025-09-11Clinical Trial Update: Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older [Phase 1]
Phase 1 trial evaluating safety and immune response of an investigational mRNA vaccine designed to prevent Respiratory Syncytial Virus infec…
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older [Phase 2]
Phase 2 study describing the safety and immunogenicity of the IN006 respiratory syncytial virus vaccine in healthy adults aged 60 and older;…
-
CLINICAL_TRIALS trial_result · 2025-09-08Clinical Trial Update: A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years [Phase 1]
Phase 1 study assessing the safety and immunogenicity of an mRNA-based RSV investigational vaccine in healthy adults aged 18-45. The trial i…
-
CLINICAL_TRIALS trial_result · 2025-08-29Clinical Trial Update: Effectiveness of Nirsevimab in Children Hospitalised With RSV Bronchiolitis
This clinical trial update reports on the effectiveness of Nirsevimab in children hospitalized with RSV bronchiolitis.
-
CLINICAL_TRIALS trial_result · 2025-08-22Clinical Trial Update: Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age [Phase 1]
Phase 1 study evaluating infectivity, safety, and immunogenicity of a recombinant live-attenuated RSV vaccine (LID/ΔM2-2/1030s) in RSV-seron…
-
CLINICAL_TRIALS trial_result · 2025-08-22Clinical Trial Update: Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older [Phase 1]
Phase 1 clinical trial evaluating safety and immunogenicity of a recombinant Respiratory Syncytial Virus vaccine in adults 18 years and olde…
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age [Phase 2, Phase 3]
This clinical trial evaluated the safety and efficacy of Moderna's RSV vaccine mRNA-1345 in adults aged 60 and older, spanning Phase 2 and P…
-
CLINICAL_TRIALS trial_result · 2025-08-17Clinical Trial Update: A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the safety of inhaled XW001 in children with Respiratory syncytial virus infection has completed.
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
Yale University is conducting a clinical study to assess real-world effectiveness of perinatal respiratory syncytial virus immunoprophylaxis…
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: Antibiotic Therapy in Viral Airway Infections [Phase 4]
This is a Phase 4 clinical trial evaluating antibiotic therapy for viral airway infections, including influenza and Respiratory Syncytial Vi…
-
CLINICAL_TRIALS trial_result · 2025-08-08Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease [Phase 3]
Phase 3 study evaluating Pfizer's RSVpreF vaccine for safety, tolerability, and immunogenicity in adults at high risk of severe RSV disease …